Form 4: Standard BioTools CFO Sells Shares to Cover Tax Obligations from RSU Vesting

Standard BioTools Inc.'s Chief Financial Officer, Hanjoon Alex Kim, sold 1,355 shares of common stock for approximately $1.002 per share to satisfy tax liabilities arising from the vesting of restricted stock units.

Summary

• Hanjoon Alex Kim, Chief Financial Officer of Standard BioTools Inc. (LAB), reported a sale of common stock.
• The transaction occurred on May 22, 2025, involving the disposition of 1,355 shares.
• The shares were sold at a weighted average price of $1.002 per share, with prices ranging from $0.9403 to $1.03.
• The sale was conducted to cover tax obligations incurred upon the vesting of restricted stock units (RSUs) granted to Mr. Kim on March 21, 2025.
• Following this transaction, Mr. Kim beneficially owns 931,714 shares of Standard BioTools common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, non-discretionary sale to cover tax liabilities from RSU vesting, which is a common occurrence and does not reflect positively or negatively on the company's operational performance or future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The shares were sold to satisfy the tax obligations that arose upon the vesting of restricted stock units granted to the reporting person on March 21, 2025.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically a sale of shares by a corporate officer. Such sales are common when restricted stock units (RSUs) vest, as employees often sell a portion of the shares to cover the associated income tax liabilities. This type of transaction is generally considered routine and does not typically indicate a change in management's sentiment about the company's prospects, unlike discretionary open-market sales.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of the total outstanding shares, but it is a routine event for tax purposes and not indicative of a change in company fundamentals or management's long-term view.
• Employees: This transaction highlights the typical process for equity compensation (RSUs) and the associated tax implications for employees.

Key Dates

Keywords

Standard BioTools, LAB, Hanjoon Alex Kim, CFO, Form 4, SEC filing, Insider transaction, Stock sale, Restricted Stock Units, RSU vesting, Tax obligations, Equity compensation